Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 25, 2017OncotargetOpen Access

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

XQXiao QuBeijing Institute of TechnologyZWZhinan WuQilu Hospital of Shandong UniversityWDWei DongKunming University of Science and Technology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Qu et al. (2017) studied this question.

synapsesocial.com/papers/6a9d7a8a9675ea02512a0a8ehttps://doi.org/10.18632/oncotarget.15704
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting the insulin-like growth factor network in cancer therapy2011 · 80 citations
  2. 2Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis2013 · 73 citations
  3. 3Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers.1992 · 123 citations
  4. 4Metformin: A Diabetes Drug for Cancer, or a Cancer Drug for Diabetics?2012 · 56 citations
  5. 5Cancer statistics, 20152015 · 11,940 citations